Trial reportSchizophrenia research2009
A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.
Trial report in Schizophrenia research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood.Twin research and human genetics : the official journal of the International Society for Twin Studies · 2015Pooled it
- Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.The American journal of psychiatry · 2013Pooled it
- Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.Schizophrenia research · 2014Trial
- Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.Schizophrenia research · 2013Trial
- Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.Pharmacogenetics and genomics · 2013Trial
- Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Psychological medicine · 2012Trial
- Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.Molecular psychiatry · 2011Trial
- Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Molecular psychiatry · 2011Trial
- Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009Trial
- Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia.JAMA network open · 2020Article
- Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.European archives of psychiatry and clinical neuroscience · 2014Article
- Clinical predictors of therapeutic response to antipsychotics in schizophrenia.Dialogues in clinical neuroscience · 2014Review
- Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group.Pharmacogenomics · 2014Article
- The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset.Schizophrenia research · 2014Article
- Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.Psychiatry research · 2014Article
- Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D.PloS one · 2013Article
- Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study.Pharmacogenomics · 2012Article
- Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Translational psychiatry · 2012Article
- Genome-wide association study of antipsychotic-induced QTc interval prolongation.The pharmacogenomics journal · 2012Article
- SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE study.Schizophrenia research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveIn addition to comparing drug treatment groups, the wealth of genetic and clinical data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness study offers tremendous opportunities to study individual differences in response to treatment with antipsychotics. A major challenge, however, is how to estimate the individual responses to treatments. For this purpose, we propose a systematic method that condenses all information collected during the trials in an optimal, empirical fashion.
methodsOur method comprises three steps. First, we test how to best model treatment effects over time. Next, we screen many covariates to select those that will further improve the precision of the individual treatment effect estimates which, for example, improves power to detect predictors of individual treatment response. Third, Best Linear Unbiased Predictors (BLUPs) of the random effects are used to estimate for each individual a treatment effect based on the model empirically indicated to best fit the data. We illustrate our method for the Positive and Negative Syndrome Scale (PANSS).
resultsA model assuming it takes on average about 30 days for a treatment to exert an effect that will then remain about the same for the rest of the trial showed the best fit to the data. Of all screened covariates, only two improved the precision of the individual treatment effect estimates. Finally, correlations between drug effects and PANSS scales suggested that in CATIE it cannot be recommended to simply combine treatment effects across drugs (e.g. to study common drug mechanisms), but it is sensible to study how a given drug affects multiple symptom dimensions.
conclusionsWe demonstrate that treatment effects can be estimated in a way that condenses all information collected in an optimal, empirical fashion. We expect the proposed method to be valuable for other clinical outcomes in CATIE and potentially other clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.